ROR1 mRNA expression in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with the T790M mutation: A potential therapeutic target

被引:0
|
作者
Karachaliou, Niki
Drozdowskyj, Ana
Costa, Carlota
Angel Molina-Vila, Miguel
Gimenez Capitan, Ana
Vergnenegre, Alain
Massuti, Bartomeu
Moran, Teresa
Majem, Margarita
Felip, Enriqueta
Carcereny Costa, Enric
Rosario Garcia-Campelo, M.
Viteri Ramirez, Santiago
Nicole Heidecke, Cordula
Estrada-Tejedor, Roger
Teixido, Jordi
Grant Bivona, Trever
Giannikopoulos, Petros
Ono, Mayumi
Rosell, Rafael
机构
[1] Pangaea Biotech, Lab Translat Oncol, Barcelona, Spain
[2] Pivotal, Madrid, Spain
[3] Cluzeau Hosp, Limoges, France
[4] Alicante Univ Hosp, Alicante, Spain
[5] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain
[6] Hosp Santa Creu & Sant Pau, Oncol Serv, Barcelona, Spain
[7] Vall dHebron Univ Hosp, Barcelona, Spain
[8] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain
[9] Complexo Hosp A Coruna, La Coruna, Spain
[10] Pangaea Biotech, Clin Unit, Barcelona, Spain
[11] Inst Quim Sarria, Mol Engn Grp, Barcelona, Spain
[12] Univ Calif San Francisco, San Francisco, CA 94143 USA
[13] Canc Therapeut Innovat Grp, New York, NY USA
[14] Kyushu Univ, Dept Med Biochem, Fukuoka 812, Japan
[15] Hosp Badalona Germans Trias & Pujol, USP Inst Univ Dexeus, Canc Therapeut Innovat Grp, Catalan Inst Oncol,Pangaea Biotech, Barcelona, Spain
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
11027
引用
收藏
页数:2
相关论文
共 50 条
  • [1] ROR1 AS A NOVEL THERAPEUTIC TARGET FOR EGFR-MUTANT NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS WITH THE EGFR T790M MUTATION
    Karachaliou, Niki
    Drozdowskyj, Ana
    Costa, Carlota
    Angel Molina-Vila, Miguel
    Gimenez-Capitan, Ana
    Vergnenegre, Alain
    Massuti, Bartomeu
    Moran, Teresa
    Majem, Margarita
    Felip, Enriqueta
    Carcereny, Enric
    Garcia-Campelo, Rosario
    Viteri, Santiago
    Heidecke, Cordula
    Estrada-Tejedor, Roger
    Teixido, Jordi
    Bivona, Trever
    Giannikopoulos, Petros
    Ono, Mayumi
    Rosell, Rafael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1048 - S1048
  • [2] ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation
    Karachaliou, Niki
    Gimenez-Capitan, Ana
    Drozdowskyj, Ana
    Viteri, Santiago
    Moran, Teresa
    Carcereny, Enric
    Massuti, Bartomeu
    Vergnenegre, Alain
    de Marinis, Filippo
    Angel Molina, Miguel
    Teixido, Cristina
    Rosell, Rafael
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (03) : 122 - 130
  • [3] Spatiotemporal T790M Heterogeneity in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer
    Hata, Akito
    Masago, Katsuhiro
    Katakami, Nobuyuki
    Imai, Yukihiro
    Yatabe, Yasushi
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (08) : E64 - E65
  • [4] Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer
    Kawamura, Takahisa
    Kenmotsu, Hirotsugu
    Omori, Shota
    Nakashima, Kazuhisa
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Omae, Katsuhiro
    Mori, Keita
    Tanigawara, Yusuke
    Nakajima, Takashi
    Ohde, Yasuhisa
    Endo, Masahiro
    Takahashi, Toshiaki
    [J]. CLINICAL LUNG CANCER, 2018, 19 (02) : E247 - E252
  • [5] Targeting the EGFR T790M mutation in non-small-cell lung cancer
    Normanno, Nicola
    Maiello, Monica Rosaria
    Chicchinelli, Nicoletta
    Iannaccone, Alessia
    Esposito, Claudia
    De Cecio, Rossella
    D'alessio, Amelia
    De Luca, Antonella
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (02) : 159 - 165
  • [6] PRETREATMENT EGFR T790M MUTATION AND BRCA1 MRNA EXPRESSION IN ERLOTINIB-TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) WITH EGFR MUTATIONS
    Rosell, R.
    Molina, M. A.
    Costa, C.
    Bertran-Alamillo, J.
    Mayo, C.
    Moran, T.
    Viteri, S.
    Mendez, P.
    Benlloch, S.
    Taron, M.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 129 - 129
  • [7] Does T790M Disappear? Successful Gefitinib Rechallenge After T790M Disappearance in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer
    Hata, Akito
    Katakami, Nobuyuki
    Kaji, Reiko
    Fujita, Shiro
    Imai, Yukihiro
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : E27 - E29
  • [8] Role of T790M Mutation in EGFR-TKI Rechallenge for Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Zhang, Qiu-Yi
    Ke, E-E
    Deng, Wei
    Niu, Fei-Yu
    Zhao, Ning
    Su, Jian
    Chen, Zhi-Hong
    Yang, Jin-Ji
    Xu, Chong-Rui
    Yan, Hong-Hong
    Wu, Yi-Long
    Zhou, Qing
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S271 - S271
  • [9] Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
    Attili, Ilaria
    Karachaliou, Niki
    Conte, PierFranco
    Bonanno, Laura
    Rosell, Rafael
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (10) : 1021 - 1030
  • [10] Predictive factors and prognostic significance of T790M mutation in patients with EGFR-mutant NSCLC
    Hwang, Ji An
    Choi, Chang-Min
    Lee, Jae Cheol
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50